NCT05377333

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 94 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	LY3457263	Administered SC.
DRUG	Placebo	Administered SC.
DRUG	Dulaglutide	Administered SC.

Timeline

• Start date: 2022-06-02
• Primary completion: 2023-11-22
• Completion: 2023-11-22
• First posted: 2022-05-17
• Last updated: 2024-01-11

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study